Cargando…
Antiviral PROTACs: Opportunity borne with challenge
Proteolysis targeting chimera (PROTAC) degradation of pathogenic proteins by hijacking of the ubiquitin-proteasome-system has become a promising strategy in drug design. The overwhelming advantages of PROTAC technology have ensured a rapid and wide usage, and multiple PROTACs have entered clinical t...
Autores principales: | Liang, Jinsen, Wu, Yihe, Lan, Ke, Dong, Chune, Wu, Shuwen, Li, Shu, Zhou, Hai-Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308200/ https://www.ncbi.nlm.nih.gov/pubmed/37398636 http://dx.doi.org/10.1016/j.cellin.2023.100092 |
Ejemplares similares
-
Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus
por: Xu, Zhichao, et al.
Publicado: (2022) -
PROTACs: great opportunities for academia and industry
por: Sun, Xiuyun, et al.
Publicado: (2019) -
Recent Advances in PROTAC-Based Antiviral Strategies
por: Ahmad, Haleema, et al.
Publicado: (2023) -
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
por: Liu, Xuelian, et al.
Publicado: (2023) -
Commentary: PROTACs make undruggable targets druggable: Challenge and opportunity
por: Lu, Bin, et al.
Publicado: (2021)